(Berkeley, CA) – Exit Strategies Group, Inc. is pleased to announce that it recently served as exclusive M&A advisor to the shareholders of US Bionics, Inc., dba suitX, on their successful acquisition by Ottobock.
SuitX is a VC, industry and government funded company spun out of the Robotics and Human Engineering Lab at the University of California, Berkeley that produces advanced accessible exoskeletons for industrial and medical markets. Germany-based Ottobock is a global innovator of prosthetics, orthotics, and exoskeletons. The companies are combining their expertise and product lines to take the exoskeleton market to a new level and foster the worldwide adoption of exoskeletons. Tony Westfall led this project for Exit Strategies Group. Deal terms were not disclosed.
“Exit Strategies Group is honored to have delivered a positive outcome for founder Dr Homayoon Kazerooni and his talented team and investors. suitX products improve the quality of lives for people with musculoskeletal injuries, reduce workplace injuries and improve human productivity in manufacturing, logistics, construction and other work environments. It is exciting to see these firms join forces to become the world leader in occupational exoskeletons, and we wish them all the best,” said Al Statz, President of Exit Strategies Group. “This deal illustrates our continued commitment to providing strategic valuation and M&A advisory services to U.S. automation and robotic technology companies.”
Exit Strategies Group (ESG) is a California-based provider of strategic merger and acquisition advice and execution, and business valuation services. Founded in 2002, with offices in San Francisco and Portland, ESG represents private companies on the sell-side and works with private equity, public and private companies and family offices on the buy-side. ESG has advised on well over 100 M&A transactions, in many industries. For more information visit www.exitstrategiesgroup.com